A box of TIRSEMA 44 by ID Labs, featuring a white and blue design with a DNA double helix graphic, set against a dark blue starry space background with a reflection below.

HD Lab Tirsema 44 | Tirzepatide 40mg + Semaglutide 4mg Combination Pen

R 2,580.00
Add to WishlistCompare

Tirsema 44 is a pre-filled, multi-dose subcutaneous injection pen combining two GLP-1 receptor-active compounds — tirzepatide (40mg) and semaglutide (4mg) — in a single solution. Manufactured by HD Labs, the pen is intended for laboratory research applications by qualified institutions studying incretin receptor pathways.

Important: this is a co-formulated blend of two distinct compounds. There is currently no published clinical research evaluating tirzepatide and semaglutide combined in a single formulation — existing research on each compound has studied them individually or compared them head-to-head, not combined. This listing describes the product's composition only; it does not imply any established safety, efficacy, or research basis for the combination itself.

Key Features
  • Format: Pre-filled multi-dose subcutaneous injection pen
  • Composition: Tirzepatide 40mg + Semaglutide 4mg per pen
  • Use restriction: Single patient/single research subject use only
  • Packaging: Boxed pen, tamper-evident seal
  • Manufacturer: HD Labs
Dosage & Usage

Research Monitoring

Studies commonly evaluate:


  • Body weight

  • HbA1c

  • Fasting plasma glucose

  • Insulin sensitivity

  • Lipid profiles

  • Blood pressure

  • Gastrointestinal tolerability

  • Laboratory biomarkers

  • Safety observations

Storage


  • Store according to the manufacturer's recommendations.

  • Protect from excessive heat and direct sunlight.

  • Do not freeze.

  • Do not use if the pen is damaged or compromised.
FAQ's & Tips

FAQ's

Q: Is this combination backed by clinical research?

A: No. Tirzepatide and semaglutide have each been extensively studied individually, and compared directly against each other in clinical trials — but there is no published research evaluating them combined into a single formulation. This product's composition is not equivalent to, or supported by, the same evidence base as either compound on its own.

Q: Is this the same as prescription tirzepatide or semaglutide products?

A: No. Both individual compounds have FDA-approved versions (Mounjaro/Zepbound for tirzepatide; Ozempic/Wegovy for semaglutide), but this combined formulation is not an approved product in any form and is not affiliated with those manufacturers.

Q: Who can purchase this product?

A: This listing is intended for qualified researchers, laboratories, and institutions conducting legitimate scientific research — not for personal or clinical use.

Q: How should the pen be stored?

A: Store according to cold-chain guidelines (refrigerated, protected from light). Refer to the product insert for exact storage specifications.

Q: What's included in the box?

A: One 44mg total (40mg tirzepatide + 4mg semaglutide) multi-dose combination pen.

Research

Tirsema combines two incretin-based compounds into a single research formulation:


  • Tirzepatide, a dual agonist of the GIP and GLP-1 receptors.

  • Semaglutide, a selective GLP-1 receptor agonist.

This combination is intended for laboratory investigation of incretin signaling and metabolic pathways. At present, there are no published peer-reviewed clinical trials evaluating a fixed-ratio co-formulation of tirzepatide and semaglutide in humans. Most published research has evaluated each compound independently.

Research Objectives

Current research interest includes evaluating:


  • GLP-1 receptor activation

  • Combined GIP and GLP-1 signaling

  • Appetite regulation

  • Energy balance

  • Glucose homeostasis

  • Body weight regulation

  • Insulin sensitivity

  • Cardiometabolic biomarkers
Reviews